Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
about
Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Trastuzumab combined with doub ...... tive metastatic breast cancer.
@en
Trastuzumab combined with doub ...... tive metastatic breast cancer.
@nl
type
label
Trastuzumab combined with doub ...... tive metastatic breast cancer.
@en
Trastuzumab combined with doub ...... tive metastatic breast cancer.
@nl
prefLabel
Trastuzumab combined with doub ...... tive metastatic breast cancer.
@en
Trastuzumab combined with doub ...... tive metastatic breast cancer.
@nl
P2093
P2860
P1476
Trastuzumab combined with doub ...... tive metastatic breast cancer.
@en
P2093
P2860
P2888
P304
P356
10.1007/S10549-017-4592-Y
P407
P50
P577
2017-11-29T00:00:00Z